Brief: Phasebio Announces European Licensing Agreement With Alfasigma S.P.A For Commercialization Of Bentracimab

PhaseBio Pharmaceuticals

17/06/2021 13:07

June 17 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO ANNOUNCES EUROPEAN LICENSING AGREEMENT WITH
ALFASIGMA
S.P.A FOR COMMERCIALIZATION OF BENTRACIMAB
    * PHASEBIO PHARMACEUTICALS INC - AGREEMENT PROVIDES PHASEBIO
WITH
$20 MILLION UPFRONT PAYMENT
    * PHASEBIO PHARMACEUTICALS - CO WILL BE ELIGIBLE TO RECEIVE
UP TO
$35 MILLION IN PRE-REVENUE REGULATORY MILESTONES
    * PHASEBIO PHARMACEUTICALS - CO WILL BE ELIGIBLE TO RECEIVE
UP TO
$190 MILLION IN PAYMENTS CONTINGENT UPON ACHIEVEMENT OF CERTAIN
SALES MILESTONES
    * PHASEBIO PHARMACEUTICALS - AGREEMENT COVERS COUNTRIES IN
EUROPEAN UNION AND EUROPEAN ECONOMIC AREA
    * PHASEBIO PHARMACEUTICALS - AGREEMENT ALSO COVERS UNITED
KINGDOM,
RUSSIA, UKRAINE AND OTHER COUNTRIES WITHIN COMMONWEALTH OF
INDEPENDENT STATES
    * PHASEBIO PHARMACEUTICALS - CO WILL BE RESPONSIBLE FOR
DEVELOPING
BENTRACIMAB,  SECURING APPROVAL WITH EMA AND MHRA

Source text for Eikon:  ID:nBw7LBzk9a 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))